

| <b>General information about company</b>   |  |
|--|--|
| Scrip code*  | 509079   |
| NSE Symbol*  | GUFICBIO   |
| MSEI Symbol*   | NOTLISTED  |
| ISIN*  | INE742B01025   |
| Name of company  | GUFIC BIOSCIENCES LIMITED  |
| Type of company  | Main Board   |
| Class of security  | Equity   |
| Date of start of financial year  | 01-04-2025   |
| Date of end of financial year  | 31-03-2026   |
| Date of board meeting when results were approved   | 14-11-2025   |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange   | 07-11-2025   |
| Description of presentation currency   | INR  |
| Level of rounding  | Lakhs  |
| Reporting Type   | Half Yearly  |
| Reporting Quarter  | Half yearly  |
| Nature of report standalone or consolidated  | Standalone   |
| Whether results are audited or unaudited for the quarter ended   | Unaudited  |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended  |  |
| Segment Reporting  | Single segment   |
| Description of single segment  | The Company's business activity falls within a single operating segment i.e. Pharmaceuticals |
| Start date and time of board meeting   | 14-11-2025 16:00   |
| End date and time of board meeting   | 14-11-2025 18:00   |
| Whether cash flow statement is applicable on company   | Yes  |
| Type of cash flow statement  | Cash Flow Indirect   |
| Declaration of unmodified opinion or statement on impact of audit qualification  | Not applicable   |
| Whether the company has any related party?   | Yes  |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?  | Yes  |
| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public  | NA   |
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | NA   |
|  | No   |

|   |   |
|---|---|
| (III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?   |   |
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?  |   |
| (b) If answer to above question is No, please explain the reason for not complying.   |   |
| Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?  | Yes   |
| Latest Date on which RPT policy is updated  | 27-12-2024  |
| Indicate Company website link for updated RPT policy of the Company   | <a href="https://gufic.com/wp-content/uploads/2024/12/Related%20party%20transactions%20policy.pdf">https://gufic.com/wp-content/uploads/2024/12/Related%20party%20transactions%20policy.pdf</a>   |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No  |
| No. of times funds raised during the quarter  |   |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?  | No<br>The Company has not defaulted in payment of interest/ instalment obligations on loans from Banks and Financial Institutions. Further, the Company does not have any outstanding debt securities (including Commercial Paper), Medium Term Notes (MTNs), Foreign Currency Convertible Bonds (FCCBs), External Commercial Borrowings (ECBs), etc. |

**Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)**

| Sr. No. | Details of the party (listed entity /subsidiary) entering into the transaction |     | Details of the counterparty |     | Relationship of the counterparty with the listed entity or its subsidiary                 | Type of related party transaction | Details of other related party transaction         | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period |                 |   | Additional disclosure of related party transactions (loans, inter-corporate deposits, advances) details need to be disclosed only once, in case monies are due to either party as a result of the transaction |      | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments |  |  |  |
|---------|--|-----|-----------------------------|-----|---|-----------------------------------|--|---|--|--|---|--|-----------------|---|---|------|---|--|--|--|
|         | Name   | PAN | Name                        | PAN |   |                                   |  |   |  |  |   | Opening balance                                  | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness   | Cost | Tenure  |  |  |  |
| 1       | Gufic Biosciences Limited  |     | Gufic Private Limited       |     | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Any other transaction             | Receiving of Services                              | 45  | Approved                               |  |   | 18.2   | 0               | -6.64   |   |      |   |  |  |  |
| 2       | Gufic Biosciences Limited  |     | Gufic Private Limited       |     | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Any other transaction             | Lease Rental paid                                  | 420   | Approved                               |  |   | 210  | 0               | 0   |   |      |   |  |  |  |
| 3       | Gufic Biosciences Limited  |     | Gufic Private Limited       |     | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Any other transaction             | Interest Free Security Deposit given against Lease |   | -                                      |  |   | 0  | 350             | 350   |   |      |   |  |  |  |
| 4       | Gufic Biosciences Limited  |     | Gufic Chem Private Limited  |     | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Any other transaction             | Lease Rental paid                                  | 48  | Approved                               |  |   | 24   | 0               | -10.96  |   |      |   |  |  |  |

|    |                           |                                    |   |                           |  |      |                |  |  |       |       |       |  |  |  |  |  |
|----|---------------------------|------------------------------------|---|---------------------------|--|------|----------------|--|--|-------|-------|-------|--|--|--|--|--|
| 5  | Gufic Biosciences Limited | Gufic Chem Private Limited         | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Any other transaction     | Interest Free Security Deposit given against Lease |      | -              |  |  | 0     | 36    | 36    |  |  |  |  |  |
| 6  | Gufic Biosciences Limited | Tricon Enterprises Private Limited | Enterprise over which Key Managerial Personnel are able to exercise significant influence | Sale of goods or services |  | 200  | Approved       |  |  | 5.86  | 8.04  | 4.85  |  |  |  |  |  |
| 7  | Gufic Biosciences Limited | Gufic UK Limited                   | Wholly Owned Subsidiary of the Company  | Investment                |  |      | -              |  |  | 0     | 54.12 | 54.12 |  |  |  |  |  |
| 8  | Gufic Biosciences Limited | Gufic Prime Private Limited        | Subsidiary of the Company   | Investment                |  |      | -              |  |  | 5.12  | 0.88  | 6     |  |  |  |  |  |
| 9  | Gufic Biosciences Limited | Veira Life FZE                     | Wholly Owned Subsidiary of the Company  | Investment                |  |      | -              |  |  | 0     | 47.52 | 47.52 |  |  |  |  |  |
| 10 | Gufic Biosciences Limited | Veira Life FZE                     | Wholly Owned Subsidiary of the Company  | Sale of goods or services |  | 8000 | Approved       |  |  | 579   | 0     | 579   |  |  |  |  |  |
| 11 | Gufic Biosciences Limited | Gufic Ireland Limited              | Wholly Owned Subsidiary of the Company  | Investment                |  |      | -              |  |  | 1.02  | 0     | 1.02  |  |  |  |  |  |
| 12 | Gufic Biosciences Limited | Mr. Jayesh P. Choksi               | Promoter, Chairman & Managing Director  | Remuneration              |  |      | Not Applicable |  |  | 58.56 | 0     | 0     |  |  |  |  |  |
| 13 | Gufic Biosciences Limited | Mr. Jayesh P. Choksi               | Promoter, Chairman & Managing Director  | Any other transaction     | Perquisites  |      | Not Applicable |  |  | 0.2   | 0     | 0     |  |  |  |  |  |
| 14 | Gufic Biosciences Limited | Mr. Pranav J Choksi                | Promoter, Chief Executive Officer & Whole Time Director                                   | Remuneration              |  |      | Not Applicable |  |  | 43.92 | 0     | 0     |  |  |  |  |  |
| 15 |                           |                                    | Promoter, Chief   | Any other transaction     | Perquisites  |      | Not Applicable |  |  | 0.2   | 0     | 0     |  |  |  |  |  |

|    |                           |  |                            |  |                       |                                    |      |                |  |  |       |       |       |  |  |  |  |  |
|----|---------------------------|--|----------------------------|--|-----------------------|------------------------------------|------|----------------|--|--|-------|-------|-------|--|--|--|--|--|
|    | Gufic Biosciences Limited |  | Mr. Pranav J Choksi        | Executive Officer & Whole Time Director        |                       |                                    |      |                |  |  |       |       |       |  |  |  |  |  |
| 16 | Gufic Biosciences Limited |  | Mrs. Pooja P. Choksi       | Immediate Relative of Key Managerial Personnel | Any other transaction | Receiving of Services              | 9.5  | Approved       |  |  | 4.75  | -0.71 | -0.71 |  |  |  |  |  |
| 17 | Gufic Biosciences Limited |  | Mr. Pankaj J. Gandhi       | Whole Time Director                            | Remuneration          |                                    |      | Not Applicable |  |  | 9.31  | 0     | 0     |  |  |  |  |  |
| 18 | Gufic Biosciences Limited |  | Mr. Pankaj J. Gandhi       | Whole Time Director                            | Any other transaction | Reimbursement of expenses paid     |      | Not Applicable |  |  | 3.48  | -0.46 | -2.16 |  |  |  |  |  |
| 19 | Gufic Biosciences Limited |  | Dr. Anu Aurora             | Independent Director                           | Any other transaction | Sitting fees                       |      | Not Applicable |  |  | 3.45  | 0     | -0.68 |  |  |  |  |  |
| 20 | Gufic Biosciences Limited |  | Mr. Kamal Kishore Seth     | Independent Director                           | Any other transaction | Sitting fees                       |      | Not Applicable |  |  | 2.75  | 0     | -0.68 |  |  |  |  |  |
| 21 | Gufic Biosciences Limited |  | Mr. Akshya Kumar Mahapatra | Independent Director                           | Any other transaction | Sitting fees                       |      | Not Applicable |  |  | 2.75  | 0     | -0.68 |  |  |  |  |  |
| 22 | Gufic Biosciences Limited |  | Veira Life FZE             | Wholly Owned Subsidiary of the Company         | Any other transaction | Reimbursement of expenses received | 25   | Approved       |  |  | 0     | 22.59 | 22.59 |  |  |  |  |  |
| 23 | Gufic Biosciences Limited |  | Veira Life FZE             | Wholly Owned Subsidiary of the Company         | Any other transaction | Advance against Import             | 8000 | Approved       |  |  | 38.23 | 0     | 38.23 |  |  |  |  |  |
| 24 | Gufic Biosciences Limited |  | Gufic Ireland Limited      | Wholly Owned Subsidiary of the Company         | Any other transaction | Reimbursement of expenses received | 25   | Approved       |  |  | 0     | 0     | 2.78  |  |  |  |  |  |

|  |        |
|--|--------|
| Total value of transaction during the reporting period | 1010.8 |
|--|--------|